News · 26 weeks91-7%
2026-04-192026-10-11
Mix3890d
- Insider21(55%)
- Other8(21%)
- SEC Filings8(21%)
- Earnings1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Pharvaris N.V.4 - Pharvaris N.V. (0001830487) (Issuer)
- PRPhase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetResults from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)Deucrictibant IR showed a well-tolerated safety profileNDA and MAA of deucrictibant IR for the on-demand treatment of HAE attacks under review by regulatory authorities ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C
- PRReal-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in TherapyZUG, Switzerland, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS) a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that insights from a Pharvaris-funded analysis of the multinational Adelphi Real World HAE Disease Specific Programme™ (DSP) dataset evaluating how HAE is managed in clinical practice have been published in Advances in Therapy. The analysis evaluated real-world patterns of HAE disease management including frequenc
- INSIDERDirector Monges Viviane exercised 11,969 shares at a strike of $8.05 and sold $395,524 worth of shares (11,969 units at $33.05) (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERPresident Lu Peng exercised 45,308 shares at a strike of $2.59, increasing direct ownership by 70% to 110,261 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERDirector Schikan Johannes Gerardus Christiaan Petrus exercised 800 shares at a strike of $20.00 and sold $28,952 worth of shares (800 units at $36.19) (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERCFO / CLO Nassif David W. sold $218,801 worth of shares (6,000 units at $36.47) and gifted 500 shares, decreasing direct ownership by 5% to 113,800 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERPresident Lu Peng exercised 100,000 shares at a strike of $2.59 and sold $3,500,000 worth of shares (100,000 units at $35.00) (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERDirector Schikan Johannes Gerardus Christiaan Petrus sold $7,000,000 worth of shares (200,000 units at $35.00), decreasing direct ownership by 63% to 115,167 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- SECSEC Form 144 filed by Pharvaris N.V.144 - Pharvaris N.V. (0001830487) (Subject)
- INSIDERDirector Bjork Elisabeth sold $1,989,409 worth of shares (52,500 units at $37.89) and exercised 52,500 shares at a strike of $15.64 (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERDirector Glassman Robert exercised 14,493 shares at a strike of $18.14 and sold $558,812 worth of shares (14,493 units at $38.56) as part of a pre-agreed trading plan (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERChief Early Development Lesage Anne sold $765,466 worth of shares (20,000 units at $38.27) (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Modig Berndt4 - Pharvaris N.V. (0001830487) (Issuer)
- SECSEC Form 144 filed by Pharvaris N.V.144 - Pharvaris N.V. (0001830487) (Subject)
- SECSEC Form 144 filed by Pharvaris N.V.144 - Pharvaris N.V. (0001830487) (Subject)
- INSIDERChief Technical Ops Officer Abele Stefan Andreas exercised 45,000 shares at a strike of $16.40 and sold $1,771,125 worth of shares (46,400 units at $38.17), decreasing direct ownership by 3% to 39,068 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERDirector Glassman Robert exercised 8,667 shares at a strike of $22.31 and sold $331,716 worth of shares (8,667 units at $38.27) as part of a pre-agreed trading plan (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERChief Commercial Officer Souverijns Wim exercised 20,000 shares at a strike of $17.43 and sold $1,023,575 worth of shares (26,090 units at $39.23) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 39,021 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERPresident Lu Peng covered exercise/tax liability with 226 shares, exercised 15,000 shares at a strike of $2.59 and sold $601,947 worth of shares (15,000 units at $40.13) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 64,953 units (SEC Form 4) (withholding obligation)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERChief Executive Officer Modig Berndt sold $90,276 worth of shares (2,291 units at $39.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 128,334 units (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- SECSEC Form 144 filed by Pharvaris N.V.144 - Pharvaris N.V. (0001830487) (Subject)
- INSIDERChief Early Development Lesage Anne exercised 30,000 shares at a strike of $8.05 and sold $1,149,084 worth of shares (30,000 units at $38.30) as part of a pre-agreed trading plan (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERDirector Glassman Robert exercised 8,000 shares at a strike of $20.00 and sold $300,396 worth of shares (8,000 units at $37.55) as part of a pre-agreed trading plan (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
- INSIDERPresident Lu Peng exercised 15,000 shares at a strike of $2.59 and sold $610,134 worth of shares (15,000 units at $40.68) as part of a pre-agreed trading plan (SEC Form 4)4 - Pharvaris N.V. (0001830487) (Issuer)
PHVS FAQ
7 questionsWhat does Pharvaris N.V. do?
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and...Where does PHVS stock trade?
Pharvaris N.V. (PHVS) is listed on NASDAQ.What sector and industry is PHVS in?
Pharvaris N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pharvaris N.V. go public?
Pharvaris N.V. (PHVS) completed its IPO in 2021.What are analysts saying about PHVS?
Pharvaris N.V. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight on 2026-07-15. Recent price targets range from $2700.00 to $4200.00.What companies are similar to PHVS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PHVS side-by-side with any of them on Quantisnow.How can I track PHVS on Quantisnow?
Quantisnow aggregates Pharvaris N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PHVS to receive live email and push alerts on every new disclosure.